Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional ...

The proposed merger of the two Cambridge drugmakers is off, but Sage says it's open to "strategic alternatives" — including a sale. Sage Therapeutics Inc. is looking for a deal — but it’s ...

Biogen has made a further push into RNA-based ... which is used as a template for protein synthesis in cells – is transformed into a mature form. As its name suggests, splicing involves snipping ...

The companies will use Sangamo’s proprietary zinc finger protein (ZFP) technology delivered via adeno-associated virus to change the expression of genes involved in these diseases. Biogen will ...

Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

An international clinical trial aimed at preventing Alzheimer’s disease (AD) in young adults who are at risk of developing ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for Alzheimer’s disease, providing a response after a meeting next month.

Protein degradation–focused Neomorph nabs its third Big Pharma deal of around $1.5 billion in less than a year.

Biogen shares soared 44 percent on a single ... drug slowed cognitive decline and the rate of accumulation of tau, a protein that creates tangles within brain cells. TD Cowen analyst Stacy Ku ...

Last Friday, Biogen offered to buy Sage Therapeutics ... an experimental drug that targets tau, a different protein found in the brains of Alzheimer's patients. "We are doubling down in Alzheimer ...